Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
ADAM10 and dyslipidemia are reported together in 1 article.
Gene
ADAM10
- HGNC
- HGNC:188
10articles
10mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Dyslipidemia
338articles
338mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
1 records shown · first 60Downregulation of CXCL16/ADAM10 axis by Simvastatin attenuates tacrolimus-induced tubulointerstitial fibrosis.
PMID 42215564 | PMCID PMC13385851 | DOI 10.1038/s41598-026-55560-3 · Scientific reports · 2026 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ADAM10 | “Downregulation of CXCL16/ADAM10 axis by Simvastatin attenuates tacrolimus-induced tubulointerstitial fibrosis.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “TAC administration resulted in significant renal dysfunction, dyslipidemia, and marked histopathological alterations, accompanied by upregulation of CXCL16, ADAM10, and fibrotic markers.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CXCL16 | “Downregulation of CXCL16/ADAM10 axis by Simvastatin attenuates tacrolimus-induced tubulointerstitial fibrosis.” | 0.98 | hgnc_dict_v1 |